Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer

Since the identification of epidermal growth factor receptor mutations (EGFR^mut+), biomarker selection of patients for specific targeted agents became the standard of care in advanced non-small-cell lung cancer (NSCLC). Small molecules against the tyrosine kinase domain of EGFR (EGFR TKIs) such as gefitinib, erlotinib or afatinib, induced impressive and durable responses in patients with EGFR^mut+, demonstrating superiority over platinum-based chemotherapy when used in front-line setting (1-3).